anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a foaming hair-dye capable of ejecting the optimum amount of stock liquid of foamed hair dye by single spraying operation by filling a stock liquid compounded with a pigment, a resin and a propellent in an aerosol container provided with a constant-volume valve and an applicator. CONSTITUTION:An aerosol can is provided with a constant-volume valve and an applicator and filled with a stock liquid produced by compounding a pigment (e.g. carbon black or Red 404), a resin (e.g. N-methacryloylethyl-N,N- dimethylammonium-alpha-N-methylcarboxybetaine butyl methacrylate copolymer), a propellent (e.g. dimethyl ether) and a foam stabilizer (e.g. polypeptide). The amounts of the pigment, resin and propellent are 0.01-15wt.%, 0.1-15wt.% and 1-30wt.% based on the stock liquid, respectively. The amount of liquid ejected by single operation is controlled to the optimum amount, i.e., 0.05-1.0ml by the action of the constant-volume valve.
Controlling cancer pain in cancer patients can be very difficult as not all cancers respond to radiotherapy or chemotherapy and sometimes the sideeffects of strong painkillers, like morphine, can limit the dose of drug that can be given. The investigators have some evidence that a molecule called Src is involved in the development of cancer-induced bone pain. This study will use a drug, saracatinib that targets Src and will see if giving it to patients can reduce pain from cancer in the bones. The investigators will compare saracatinib to a placebo over a 4 week period in an estimated 62 patients. The investigators will measure whether the pain that patients report is less with saracatinib than placebo. The investigators will also measure how many painkillers people are taking before and after saracatinib/placebo, if pain thresholds have changed, if pain-related symptoms and quality of life have been improved and if saracatinib has a direct effect on the rate at which cancer breaks down bone.
PURPOSE:To enable obtaining of an antihuman tenascin monoclonal antibody in high yield by culturing a hybridoma cell capable of producing a monoclonal antibody specifically reactive with human.tenascin. CONSTITUTION:A human fibroblast cell is extracted with a urea-containing extracting solution, etc., to provide an extract solution, which is then subjected to treatment, such as salting out or gel filtration, and then purified with an anionic type ion exchange resin for separating biopolymers to afford a high- purity tenascin (A), which is then used to immunize a mouse, etc. The spleen of the immunized mouse is subsequently extirpated to afford an immunized splenic cell (B). The resultant cell (B) is subsequently fused to a mouse myelomatous cell (e.g. PAI) (C) to provide a hybridoma, which is then cloned to afford a hybridoma HTN-9B2 cell (D). The obtained cell (D) is subsequently cultured in an RPMI 1640/10%-FCS culture medium, etc., to produce an antihuman.tenascin monoclonal antibody. The cell (D), as necessary, is transplanted to a nude mouse to produce a monoclonal antibody specific to ascitic type human.tenascin.
Blood-brain barrier (BBB) disruption is increasingly recognized as an early contributor to the pathophysiology of cerebral ischemia/reperfusion (I/R) injury, and is also a key event in triggering secondary damage to the central nervous system. Recently, long non-coding RNA (lncRNA) have been found to be associated with ischemic stroke. However, the roles of lncRNA in BBB homeostasis remain largely unknown. Here, we report that long intergenic non-coding RNA-p21 (lincRNA-p21) was the most significantly down-regulated lncRNA in human brain microvascular endothelial cells (HBMECs) after oxygen and glucose deprivation/reoxygenation (OGD/R) treatment among candidate lncRNA, which were both sensitive to hypoxia and involved in atherosclerosis. Exogenous brain-endothelium-specific overexpression of lincRNA-p21 could alleviate BBB disruption, diminish infarction volume and attenuate motor function deficits in middle cerebral artery occlusion/reperfusion (MCAO/R) mice. Further results showed that lincRNA-p21 was critical to maintain BBB integrity by inhibiting the degradation of junction proteins under MCAO/R and OGD/R conditions. Specifically, lincRNA-p21 could inhibit autophagy-dependent degradation of occludin by activating PI3K/AKT/mTOR signaling pathway. Besides, lincRNA-p21 could inhibit VE-cadherin degradation by binding with miR-101-3p. Together, we identify that lincRNA-p21 is critical for BBB integrity maintenance, and endothelial lincRNA-p21 overexpression could alleviate cerebral I/R injury in mice, pointing to a potential strategy to treat cerebral I/R injury.
Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 8 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
The program of treatment will be 3 times a week lasting for 8 weeks. A standardized 5- min warm-up phase will precede each session and 10-min cooling down phase after each session with the actual time of each session is 30 minute. 30 minutes of virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller).
BACKGROUND: NICU admission for hypothermia is a problem worldwide, with associated morbidity, mortality, and financial costs. Many interventions have been studied for smaller infants, but there has been little focus on infants born ≥34 weeks' gestational age (GA), though most deliveries occur at this gestation. Our primary aim was to improve the proportion of infants ≥34 weeks' GA with normal NICU admission temperature. Secondary outcomes included improvement of the proportion of normal first temperature in all infants ≥34 weeks' GA, independent of NICU admission, and improvement of predefined outcome measures.
METHODS: We completed a root cause analysis, using fishbone and process mapping to determine what factors were contributing to hypothermia. A series of changes were trialed using plan-do-study-act cycles to develop a standard operating procedure, covering both vaginal and cesarean section births. Outcome measures were analyzed using a P-chart as well as traditional statistical tests.
RESULTS: We successfully increased the proportion of infants ≥34 weeks' GA with normothermia on NICU admission from 62% to 80% without increasing hyperthermia. In addition, the interventions improved the proportion of delivery room normothermia in all infants born ≥34 weeks' GA and were associated with a decreased need for intravenous therapy for hypoglycemia and the incidence of metabolic acidosis.
CONCLUSIONS: This quality improvement initiative was successful at improving our institution's rates of normal infant temperature. The methodology used can be applied to other similar centers to improve this common problem.
All subjects will enter PHASE 1 and will receive a full course of routine ECT (maximum of 6 weeks and 3 treatments per week) while being on stable antipsychotic medication. All ECT-responders (patients with improvement of 30% or more on Brief Psychiatric Rating Scale (BPRS) will enter PHASE 2 and will be randomly assigned to the active comparator (mECT plus treatment-as-usual, TAU) or the control intervention (TAU) which both last 28 weeks. Non-responders (patients without improvement of at least 30 % on BPRS scale) will not enter PHASE 2.
The invention provides a traditional Chinese medicine composition used for treating Alzheimer's dementia. The composition comprises traditional Chinese medicine raw materials used as active components, and pharmaceutic adjuvants. The traditional Chinese medicine raw materials used to prepare the active components comprise 6-12 weight parts of polygala root, 10-20 weight parts of radix codonopsis and 5-15 weight parts of liquorice. According to the invention, effects on quasi-AD rats diseases of which are caused by injection of A[beta]1-40 to bilateral hippocampus, effects on memory acquisition disorder type AD model mice diseases of which are caused by scopolamine, and the like are tested. Test results show that the composition can improve learning and memory abilities of the AD model rats, and can increase intracephalic energy metabolism, thereby improving brain functions, etc.. Therefore, the traditional Chinese medicine composition can be applied for preparing medicines used for treating the Alzheimer's dementia. The composition is in forms of tablets, capsules and granules, thus improving medicine taking compliance for patients. The preparations are stable and easily prepared, and suitable for industrial production. New medicines used for treating the Alzheimer's dementia are provided for clinic. The composition has great application value and social benefit.
The control group will receive sterile normal saline solution, serving as placebo, IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of placebo IV postoperatively 24 and 48 hrs. Both Dexamethasone and normal saline solution will be administered as an IV push.
A composite material and method of preparing same for use in prosthetic dentistry. The composition includes silica glass containing between about 8.0-30% on a weight basis of alkaline earth metal oxides and/or alkali metal oxides in solution selected from the group consisting of calcium oxide, magnesium oxide, sodium oxide, potassium, and lithium oxide. In one form of the invention, a methacrylate resin is coupled to the silica glass by a silane mixture. The invention includes the method of forming the composite material through both a cold curing system and a heat cured system into a composite veneering and tooth material which is useful in forming crowns and other dental restorations as well as artificial teeth requiring aesthetic appearance of normal dentition. The finally formed dental material shows a high hardness factor in combination with a high wear resistance. The composite material has the capability of being highly polishable and provides for low toxicity as well as a low index which allows optical matching of the composite material to naturally formed teeth.
BACKGROUND: Biomarkers predictive of disability outcomes in individual multiple sclerosis (MS) patients undergoing autologous haematopoietic stem cell transplantation (AHSCT) are currently lacking. As correlations between spinal cord atrophy and clinical disability in MS were previously described, in this study spinal cord size was investigated in MS patients treated with AHSCT, exploring whether baseline spinal cord volume may predict disability progression after AHSCT.
METHODS: relapsing-remitting (RR-) and secondary-progressive (SP-) MS patients treated with AHSCT (BEAM/ATG regimen) at a single academic centre in Florence, who performed at least two standardized brain magnetic resonance imaging (MRIs) scans (acquired between one-year pre-AHSCT to 5 years after AHSCT) were included. Cervical spinal cord atrophy was estimated as upper cervical spinal cord cross-sectional area (SCCSA). Brain volume loss (BVL) was analysed at the same timepoints.
RESULTS: Eleven (8 RR-; 3 SP-) MS patients were included. Over a median follow-up of 66 (range 37 - 100) months, no relapses nor brain MRI activity were observed; disability progressed in 2 cases (both SP-MS). Baseline SCCSA was associated with EDSS change between pre- and one-year post-AHSCT. Compared to patients who stabilized, patients who progressed after AHSCT tended to have lower SCCSA at C4 level at baseline and year 1 after AHSCT. Longitudinal changes in SCCSA or BVL did not correlate with EDSS change.
CONCLUSIONS: Baseline pre-AHSCT SCCSA, but not its longitudinal changes nor BVL, predicted EDSS change within the two years following AHSCT. SCCSA may represent a biomarker of treatment response and a promising screening tool for assessing patient eligibility for high-impact treatments such as AHSCT.
Consistent adherence to antiretroviral therapy (ART) is important to maintain viral suppression and good quality of life among people living with HIV. However, maintaining a high level of ART adherence is challenging because adherence is a complex behaviour and many factors contribute to nonadherence. Therefore, a decision support tool is proposed to help HIV care providers in addressing the barriers and providing the adherence-promoting interventions tailored to the individual needs. The present study comprises a usability assessment followed by a cluster randomised controlled trial to investigate the effectiveness of the adherence toolkit as a decision support tool on improving adherence to ART. Twelve HIV clinics in Surabaya, Indonesia, will be randomised 1:1 to the control (usual care) and intervention (adherence toolkit and usual care) group. The intervention period will last for 12 months, with outcome measures will be collected at initiation, 3-, 6-, and 12-month post-initiation. The primary outcome is adherence to ART measured using a self-reported adherence questionnaire and pharmacy refill records. The secondary outcomes include clinical outcomes (viral load, CD4), HIV treatment knowledge, medication beliefs, and health-related quality of life. The findings will enable HIV care providers, people living with HIV, and policy makers to make informed decision about the value of the adherence toolkit for being used in daily clinical practice.
Fencing is an agility sport, with higher incidence of injuries in the lower limbs, with the ankle sprain the most prevalent. Injury prevention is very important to improve performance and reduce time off of athletes. Proprioceptive training programs can be added to the training of athletes, since in addition to the easy application and low cost, proprioception serves to stabilize the joint, preventing injuries. Therefore the aim of this study is to investigate the influence of a 12-week proprioceptive training program on the neurofunctional control and the incidence of ankle sprains in fencing athletes. The study will be a randomized clinical trial, with fencing athletes from 14 to 25, a multi-sport club of Porto Alegre/RS, and developed in six stages: familiarization, pre intervention, intervention, post intervention follow-up of three and six months. The first step will be to familiarize themselves with the force of testing and registration of injuries in the previous year. In the pre intervention stage will evaluate muscle strength inverters, everter, dorsal plantar flexors and ankle flexors through the isokinetic dynamometer; the reaction time of these muscles during Lunge Test; neuromuscular control during the Star Excursion Balance Test and performance in Drop Vertical Jump Test. In the intervention athletes will perform proprioceptive training for 12 weeks, three times a week, lasting 30 minutes. In the post intervention, the follow up of three to six months will be held the same pre intervention of the tests and recording the incidence of injuries occurred during the study. For statistical analysis, the data will be presented as mean and standard deviation and submitted to the Shapiro-Wilk test, ANOVA will be held for repeated measures and post hoc Bonferroni to determine differences. The effect size is calculated using Cohen's d test.o significance level is 0.05. The expected result at the end of the study is to improve all variables, increasing the performance of athletes and decreasing the incidence of ankle sprains.
Severe aplastic anemia (SAA) is a disorder with a poor prognosis if untreated. Current accepted therapeutic strategies include bone marrow transplantation (BMT) and immunosuppression, both offering cure or amelioration in the majority of patients. Although BMT is successful using human leukocyte antigen (HLA) matched sibling bone marrow, the 25% probability of finding an HLA identical sibling within a family renders this approach available to only a minority of patients. BMT utilizing HLA-matched, unrelated donors carries a high risk of treatment failure along with considerable toxicity. While combined immunosuppression with both antithymocyte globulin (ATG) and cyclosporine A (CSA) produces hematologic improvement in most patients, relapse is common, occurring in about a third of responders. Late evolution of aplastic anemia to other serious hematologic disorders is a significant problem following successful treatment with ATG/CSA with paroxysmal nocturnal hemoglobinuria (PNH) occurs in approximately 13%, myelodysplasia in about 10%, and acute leukemia in about 7%. Recently, results of immunosuppression in SAA with another potent immunosuppressive agent, cyclophosphamide, were reported in 10 patients. In this small group, the overall response rate was similar to that seen with ATG/CSA, but relapse and late clonal disease were not seen during a median follow-up of greater than 10 years. In the larger randomized trial proposed here, we will compare sustained hematologic response rates to either conventional immunosuppression with ATG/CSA or high dose cyclophosphamide and CSA. Secondary endpoints include response duration, event free survival, and overall survival.
The objective of this research is to evaluate the impact of a multi-level behavior change intervention designed to promote toilet construction, exclusive toilet use and maintenance in peri-urban communities of Tamil Nadu. The intervention leverages two years of formative research and reflects a norms and network-centric approach that will employ dynamic information dissemination to signal others' sanitation practices while also addressing other barriers to the adoption of improved sanitation practices. The study will determine whether those who received the interventions had significant improvements in toilet usage compared to those who did not.

For this cluster-randomized trial, communities will be engaged in two rounds of surveys to assess toilet ownership, toilet usage practices of their family members and include additional questions about beliefs, norms and other factors influencing toilet use. Investigators will also conduct a process evaluation to monitor change from baseline to endline and identify successful pathways of or bottle-necks to the adoption of improved sanitation behaviors. These indicators will include fidelity indicators to assess the quality of intervention delivery, level of community participation, behavioral antecedents, contextual changes in community and household conditions that may facilitate improved behavioral adoption and/or outcomes (e.g., exclusive toilet use). They will also conduct qualitative research using observations and semi-structured interviews with respondents and stakeholders to assess exposure and reactions to the intervention. They will also assess spillover in the control wards using mixed-method assessment tools.
Much progress has been made in implementing potent antiretroviral therapy that is able to maximally suppress viral replication. However, these drug combinations do not result in viral eradication and, for many patients, virologic and immunologic control cannot be maintained. Even among patients with apparent virologic control, a "ceiling effect" seems to exist with failure of CD4 cell counts to rise on average more than 100 to 150 cells/mm\^3, at least during the first 2 years of therapy. The incomplete recovery of immune function after initiation of therapy remains an obstacle in the management of HIV. Preservation of immune function by direct expansion of CD4 lymphocytes with rIL-2 could represent a significant additional treatment strategy. It also has been speculated recently that rIL-2 in combination with potent antiretroviral therapy may be a useful approach for purging HIV from the latently infected CD4 cells. It is hoped that intervention with rIL-2 therapy in combination with antiretroviral therapy at an early stage of HIV infection can prevent CD4 T-cell depletion and result in fewer AIDS-defining illnesses than with antiretroviral therapy alone.

Patients are randomized to receive subcutaneous (SC) rIL-2 therapy or no rIL-2 therapy. All patients must be taking a regimen of combination antiretroviral treatment, with the choice of therapy at the discretion of the treating clinician. Antiretroviral medications are not provided by this study. Recombinant IL-2 is given SC for 5 consecutive days every 8 weeks for at least 3 cycles unless toxicities or other contraindications develop. After the first three cycles, additional cycles are given at the discretion of each patient's physician, with a general goal of maintaining the patient's CD4 cell count at twice the baseline level or at 1,000 cells/mm\^3 or above for as long as possible. Patients in the no rIL-2 group receive no injections. Patients in both treatment groups are seen every 4 months for follow-up data collection to monitor viral load and CD4 cell counts. All patients are followed for a minimum of 4 years. During the trial, patients in the no SC rIL-2 group are not given rIL-2 at any point. However, at the end of the study, if rIL-2 is found to be effective in reducing the rate of disease progression \[AS PER AMENDMENT 12/15/00: (new and recurrent events)\], including death, all patients are offered rIL-2.
The research will be carried out on 30 cases diagnosed with cervical disc herniation between the ages of 18-65. The patients will be divided into 2 groups as control and experimental groups by simple randomization method. While the conservative physical therapy program is applied to the control group, the patients in the experimental group will be applied 1 day graston and 1 day dry cup technique in addition to the ones in the experimental group. All patients will be treated for 20 sessions, 5 days / 4 weeks. Fremantle Neck Awareness Questionnaire to assess neck awareness, hand dynamometer to assess grip strength, Berg Balance Scale to assess balance and Jenkins Sleep Scale to assess sleep quality will be used. All tests will be measured at the start of treatment and after 4 weeks of intervention. Pre- and post-intervention data were statistically analyzed and compared.
PURPOSE:To alarm a nap always in an optimum manner by detecting brain waves of a driver further analyzing a frequency while judging warning action in accordance with a level of slow alpha frequency component when nap warning is generated in accordance with the frequency. CONSTITUTION:A device detects a brain wave in a means 1, further amplifying the detected brain wave in a means 2 while removing a noise of amplified signal in a means 3. A frequency of the signal removing the noise is analyzed in a means 4. Here the means 4 is constituted of a band pass filter allowing only a slow alpha frequency component to pass through. Hereafter being based on an analytic result of the frequency, an alarm is generated in a means 5. Thus reducing misoperation while generating the alarm in the good timing just before a nap, it is easily further surely prevented.
PROBLEM TO BE SOLVED: To obtain a cosmetic composition for applying to the skin or hair, improved in transfer resistance, by combining trimethylated silica, a specific volatile solvent, a specific nonvolatile oil, and a carrier. SOLUTION: This cosmetic composition comprises about 0.1-60 wt.% of trimethylated silica (pref. 0.5-100 μm in average particle size), 0.1-60 wt.% of a volatile solvent having a viscosity of 0.5-100 cP at 25 deg.C (e.g. a cyclic silicone), about 0.1-60 wt.% of a nonvolatile oil having a viscosity of 200-1000,000 cP at 25 deg.C (e.g. a nonfluorinated silicone), and about 0.1-80 wt.% of a cosmetically acceptable carrier. This composition forms a film not transferring onto clothing or household commodities, being capable of forming a cosmetic film reduced in the infiltrativity against oil and water.